In the past decade in vitro tests have been developed that represent a range of anatomic structure from perfused whole organs to subcellular fractions. To assess the use of in vitro tests for toxicity testing, we describe and evaluate the current status of organotypic cultures for the major target organs of toxic agents. This includes liver, kidney, neural tissue, the hematopoietic system, the immune system, reproductive organs, and the endocrine system. The second part of this report reviews the application of in vitro culture systems to organ specific toxicity and evaluates the application of these systems both in industry for safety assessment and in government for regulatory purposes. Members of the working group (VWG) felt that access to high-quality human material is essential for better use of in vitro organ and tissue cultures in the risk assessment process. Therefore, research should focus on improving culture techniques that will allow better preservation of human material. The WG felt that it is also important to develop and make available relevant reference compounds for toxicity assessment in each organ system, to organize and make available via the Internet complete in vivo toxicity data, including human data, containing dose, end points, and toxicokinetics. The WG also recommended that research should be supported to identify and to validate biological end points for target organ toxicity to be used in alternative toxicity testing strategies.
Introduction
Detecting specific organ toxicity is critical to toxicity testing. Current in vivo The most physiological organ preparation for toxicity studies is the isolated perfused organ. This system maintains tissue architecture that allows for cell-cell interactions and measurement of organ secretory/excretory activity. However, the main disadvantages are that it does not reduce the number of animals used and there is significant variability between animals.
The next level of tissue organization available for toxicity testing is tissue slices. These have been successfully prepared from liver, heart, kidney, and brain, to name a few. Although tissue architecture is maintained, cell preservation is problematic. Isolated suspended cell preparations are used for blood cells, including cells of the immune system. This works well for short-term studies.
The first part of this report updates the current status of organotypic cultures for the major target organs of toxic agents. This includes liver, kidney, neural tissue, the hematopoietic system, the immune system, reproductive organs, and the endocrine system. The second part reviews the application of in vitro culture systems to organ-specific toxicity and evaluates future prospects.
Current Methods for Organotypic Cultures
Liver In vitro models of liver toxicity are detailed by Guillozo (1) . The Because the isolated organ model is difficult to handle and cannot be used for human studies, tissue slices and isolated hepatocytes, either in suspension or in primary culture, are currently the most powerful models (4, 5) . They reflect the in vivo situation, at least for a few hours, and can be obtained from various species including humans and fish (1, 2 The isolated perfused nephron is not suitable for routine investigations, but this system provides data on enzyme localization and receptor distribution, which can be used for confirming the site of origin of isolated cells (12) .
Renal slices have been used extensively in the past for renal transport and toxicity studies, typically for no more than a 2-hr period (13 (16) (17) (18) . Positive results in these Tier 2 studies would provide the basis for further tests that may include neurochemical or electrophysiological experiments, and are aimed at characterizing neurotoxic effects and identifying possible mechanisms. Special considerations, and additional testing, should be given to organophosphorus compounds (for their ability to cause delayed neuropathy) and to developmental neurotoxicants. As in other areas of toxicology, the desire to reduce the number of animals, and the time and costs of testing, has led to exploration of the possible use of in vitro approaches for neurotoxicity testing.
Several in vitro systems can be considered as alternative testing systems for Environmental Health Perspectives * Vol 106, Supplement 2 * April 1998 neurotoxicity (19) (20) (21) (22) . In decreasing order of complexity these models include organotypic explants, brain slices, reaggregate cultures, primary cell preparations, and established cell lines. Each model system has advantages and disadvantages. For example, all are derived from animals (rats or chicken) with the exception of cell lines and, in some occasions, primary cultures. In some systems, for example, organotypic explants or brain slices, the cytoarchitecture of the nervous system or certain neuronal circuitries or biochemical processes are preserved. On the other hand, primary cultures or cell lines allow the study of the effects of toxicants on isolated cell types (e.g., neurons, astrocytes, oligodendrocytes). Cell lines are usually the simplest to manipulate, but present the problem of being transformed, and may potentially display altered responsiveness (e.g., resistance) to toxicants. Systems that involve coculture of cells are also available, such as cocultures of neurons and astrocytes or oligodendrocytes, or astrocytes and endothelial cells, to mimic in vitro the blood-brain barrier (23) .
Hematopoietic System Leukocytes (granulocytes, monocytes, lymphocytes), erythrocytes, and platelets circulate in the blood where they perform specialized functions essential in immunity, oxygen delivery, and blood clotting. A hematotoxicant is defined as an external substance that causes a clinically significant adverse effect on the level or function of these cells (24) (25) (26) (27) (28) . Decreased cell number is known as cytopenia and increased cell number cytosis. Blood cells are produced by precursor cells called progenitors, which are found in the bone marrow (and spleen of some animals). In vivo, hematotoxicants act by direct effects on blood cells or their progenitors, or by indirect effects mediated by humoral factors (24) (25) (26) (27) (28) . The availability of recombinant cytokines has stimulated the development of in vitro assays for many progenitor populations in the myeloid, erythroid, platelet, lymphoid, and stromal lineages (26) , and these progenitors have been cocultured with hepatocytes or transgenic cells to study bioactivation (e.g., via CYP) of protoxicants (25) . Clonogenic assay for the neutrophil monocyte progenitor called colony forming unit-granulocyte/macrophage (CFU-GM) has been most commonly applied by laboratories in academia, industry, and government to the study of hematotoxicants in several species, including human (25) (26) (27) , so SGOMSEC 13 focused on the evaluation of direct effects of toxicants on hematopoietic progenitors (28) . Direct effects of toxicants on circulating blood cells (e.g., hemolysis) have been routinely assessed ex vivo and are not covered in detail in this workshop. Immune System In vitro models suitable for study of immune system toxicity are detailed by Karol (29, 30) . The immune system is a multicellular, multiorgan complex that includes the spleen, thymus, lymph nodes, and tonsils, as well as lymphoid areas of the gut and lung. The function of the immune system is to protect against agents such as bacteria, viruses, and particulates in the external environment, as well as against the internal development of "nonself' neoplasms. Dysfunction of the immune system is recognized as either heightened immune reactivity, as in hypersensitivity disease, or reduced immune surveillance that is manifested as reduced ability to combat infectious agents or tumors. Lymphoid cells from the blood, lymph nodes, and spleen, and fixed immune cells from solid tissues can all be isolated and studied ex vivo. Some of these cells can proliferate in response to added growth factors, whereas others are terminally differentiated and their specialized functions can be assessed.
Reproductive Organs
Reproduction is a continuous cycle, but for the purpose of toxicity testing it is divided into pregnancy, including prenatal and postnatal developmental toxicity, and the remainder of the reproductive cycle in both males and females when fertility may be impaired. To evaluate the reproductive toxicity of chemicals to humans, investigators conducted multi-generational studies in laboratory animals to provide information on the effects of industrial chemicals on all aspects of the highly complex reproductive cycle (31) . In drug development, segment studies are conducted covering important phases of pre-and postnatal development as well as fertility (32) . Because the complexity of the reproductive cycle and because of the lack of validated alternative tests for most of the steps in the cycle, testing in living animals is the only option currently available for assessing the possible effects of chemicals on reproduction.
To study fertility in vitro, methods for culturing ovarian and testicular cells and tissues both from laboratory animals and humans are established. Moreover, in vitro fertilization and embryo transfer, including the production of transgenic animals, are currently used worldwide in laboratory animals, farm animals, and for most of the techniques, also in humans. Therefore, techniques to assess the viability of sperm and oocytes to fertilize are in clinical use for both animals and humans (33) .
Ex vivo cultivation of whole embryos is used to evaluate toxic effects on prenatal development in mammals, including humans. From fertilization to implantation, mammalian and human embryos can routinely be cultured. For the common rodent species, fairly simple whole-embryo culture techniques have been developed that usually start at the primitive streak stage and allow development to the most important phases of organogenesis. The usual culture period during which there is acceptable progress in development is usually 24 hr or less (34) .
The development and differentiation of the most important embryonic organs can be studied in culture, for example, development of the limbs, heart, teeth, thyroid gland, central and peripheral neural tissue, and closure of the palatel shelves. The induction of embryonic tissues by other tissues, including induction of somites, the spinal cord and other organs, as well as interactions among tissues and the effects of growth factors and hormones, can be studied in specially designed systems, for example, transfilter systems (33, 34) .
Cells of almost all embryonic organs of mammals and most vertebrates can be maintained in primary culture. To Table 6 .
An important parameter for evaluating nephrotoxicity of a chemical is the measurement of epithelial leakiness with Environmental Health Perspectives * Vol 106, Supplement 2 * April 1998 indicator compounds, or the more sensitive end point of transepithelial electrical resistance generated by the vectorial transport of ions. Epithelial leakiness has been shown to be more sensitive than biochemical measures (enzyme leakage) for renal epithelial cell injury (46) .
In vitro systems are well suited for studying interactions of chemicals with cellular structures. Initially the time-and dose-response relation should be explored. Neural Tissue. In vitro systems are amenable and very useful for mechanistic studies at the cellular and molecular level. As such, they have been used extensively in neurobiology and, to a minor extent, in neurotoxicology. As one of the problems of neurotoxicological research is the limited knowledge of mechanisms of neurotoxic damage, in vitro systems offer a useful way to apply biochemical, morphological, molecular biology and imaging techniques to the achievement of this goal (18, 19) .
When in vitro systems are considered as screening tools for detecting putative neurotoxicants, two important issues to be considered are the cell systems to be used and, most importantly, the end points to be measured (20, 27) . Suggested approaches involve the use of a battery of cell types such as a neuronal and a glial cell line, a more complicated system, and a nonnerve cell line. End points to be measured in vitro should include indicators of cytotoxicity, viability, as well as of neurotoxicity. Comparisons between nerve and nonnerve cells would offer indication of whether a chemical may have differential effects or display different potencies in these different cell types. However, it would still be an indication of cytotoxicity rather than neurotoxicity. Several end points for neurotoxicity have been proposed and many more could be suggested; these include enzymes, receptors, second messenger systems, ion channels, etc. Because of the complexity of the nervous system and the large number of potential targets, the choice of end points is crucial to avoid false positives and false negatives.
Hematopoietic System
The CFU-GM assay is the most frequently used progenitor assay in toxicology (24) (25) (26) (27) (28) . It meets important prerequisites, including ease of use and portability between laboratories, low expense, high interlaboratory reproducibility, and the ability to assess toxicant effects on the actual target cell in humans (25) . At this time, it is important to recognize that CFU-GM data are most meaningful when neutropenia is the likely in vivo toxicity (26) . The in vivo end point of toxicity to be predicted with the CFU-GM assay is a reduction in the number of neutrophils in Environmental Health Perspectives * Vol 106, Supplement 2 * April 1998 the blood. There is a relationship between progenitor numbers and blood-cell counts in vivo, so it should be possible to predict the reduction in CFU-GM in vivo, and thereby the decrease in neutrophil counts, from the toxicant-dependent inhibition of CFU-GM in vitro (35) .
Currently, none of the in vitro hematopoietic assays has been validated for toxicological purposes, although an European Centre for the Validation of Alternative Methods (ECVAM)-supported validation study will focus on the CFU-GM assay for predicting the level of acute exposure that causes severe neutropenia (25) . In clinical oncology, the IC90 end point from the CFU-GM test is used for comparative toxicology of an investigational antineoplastic agent in humans, mice, rats, or dogs to determine if dose adjustment is required and to derive pharmacological targets for dose escalation (26, 28, (48) (49) (50) . In cases of extreme differences in hematotoxicity between species, the CFU-GM assay could be used instead of hematology studies in primates. In pharmaceutics, the CFU-GM assay has been used to identify and halt the development of antiviral nucleoside analogues that would likely be myelosuppressive in humans (27) . This assay also could be useful in guiding the development of antineoplastics that show activity against human tumor xenografts primarily because they are human-selective toxicants, rather than tumor-selective agents (50) . When viewed as preclinical toxicology and used for early decisions in drug development, comparative CFU-GM toxicology could be a justification to cancel a compound that will likely cause unacceptable hematotoxicity clinically and thereby avoid useless animal toxicology.
In the near future, the CFU-GM assay could be a useful adjunct to test number 407 of the Organisation of Economic Co-operation and Development (OECD) Guidelines for Testing of Chemicals (28-day repeat-oral dose toxicology). The usual species is rat, but other species are allowed, and comparative in vitro toxicology in the CFU-GM assay might suggest an alternative species that is closer than the rat to human sensitivity. It could also find use as an adjunct test when rat histopathology or hematology (absolute neutrophil count) indicate bone marrow toxicity, to determine if humans will be more or less sensitive than the rat. As soon as an in vitro end point is identified that predicts the hematologic no observable adverse effect level (NOAEL), the assays of hematopoietic progenitors could prove useful for predicting the acute permissible exposure limits for human marrow of food contaminants and additives, industrial chemicals and environmental pollutants, and chronically administered medications (15, 16, 18, 33) . For prioritizing regulatory research on potential human hematotoxicants, it could be helpful to determine if human CFU-GM is inhibited at exposure levels that occur in the tissue of exposed individuals which do not lead to clinically detectable neutropenia.
Immune System. Most of the assays used to detect immunotoxicity are performed in conjunction with the standard 28-day rodent toxicity testing protocol of Karol (51) . However, in the United States, mice, rather than rats, are more commonly used in immunotoxicity testing (52, 53 (44) .
Although the mechanisms of skin and respiratory hypersensitivity have not been fully elucidated, several steps in the initiation phase of the process are understood. For dermal sensitization the process is initiated by penetration of the agent through the epithelial barrier, followed by interaction with a carrier molecule. Simple mechanistic tests have been developed to address this phase of the process (60) . One test, the local lymph node assay (LLNA), uses mice and examines the ability of chemicals to stimulate proliferation of lymph node cells (43) . The test has undergone a validation trial and has been accepted by OECD for regulatory use. Another method well suited to assessment of sensitization potential of chemicals uses structure-activity relationships (SAR) (45) . Several SAR models have been described for dermal sensitization and typically incorporate a parameter to estimate penetration of the skin (usually log P), and a reactivity parameter (dipole moment). Such models have been found to have a sensitivity and specificity approaching 90%.
SAR is also being developed to estimate the hypersensitivity of potential respiratory allergens. Preliminary validation of this methodology indicates a sensitivity of 86% and specificity of 95%. Other mechanistic methods are being applied to predict respiratory hypersensitivity. As IgE antibody has been implicated as contributing to the mechanism of some chemical respiratory allergies, assessment of the concentration of IgE in serum has been proposed as a screen for chemical respiratory allergy. The test is performed in mice and awaits validation studies with both positive and negative chemicals (43, 45) .
Other mechanistic assays used to estimate the potential of a chemical to elicit respiratory hypersensitivity include the basophil histamine release assay and cellular production of cytokines (59, 61) . Histamine is known to contribute to the airway constriction that typifies allergic airway sensitivity and cytokines are proinflammatory mediators released from numerous immune cells. These assays are typically conducted in rodent species. Measurement of cytokines in serum or bronchial lavage and release of cytokines from bronchoalveolar cells also have been done in humans. These tests measure one end point of hypersensitivity and should be used in conjunction with other assays to better assess the allergic potential of a chemical.
Reproductive Toxicology. All of the established in vitro methods are currently used to study adverse effects of chemicals and physical agents on fertility and development in mammals. Special problems can be assessed on human material, e.g., transfer of chemicals into tubular and uterine fluid as well as into sperm and seminal fluid. These methods have been used as adjunct tests to the current long-term in vivo studies in rodents both for the safety assessment of drugs and for risk assessment of existing chemicals (34) .
Whole embryo culture systems have been established in industry for screening purposes and mechanistic studies. Because the test is difficult to standardize, it has been used succcessfully in only a few laboratories. The whole embryo culture assay underwent several standardization and validation trials in Europe (63) . For a given group of structurally related chemicals, the whole embryo culture assay can be used inhouse for screening purposes. Limb bud cultures, brain cell aggregates, cultures of palatal shelves, embryonic lung, and many other organs both from rodents and even human tissues, and organs from aborted fetuses have been used extensively for mechanistic studies as adjunct tests to standard embryotoxicity tests in rodents (33, 34 (65) . A standardized protocol micromass assay was tested in an international validation trial, and Flint reported in 1993 that this assay correctly identified chemicals that are known to be teratogenic both in humans and the most common rodent species. These data have not been published. A validation trial of the micromass assay in the Netherlands was less successful, therefore the micromass assay has become less popular, even though it had been established in both industry and contract testing facilities.
A validation trial that examined both the whole embryo culture assay and micromass assay showed that the predictive value is considerably improved when the two assays are combined (66) . Since the two tests require special equipment and a trained staff, they are established only in contract testing facilities. None suggested that a battery of in vitro and in vivo assays can be used in a tiered strategy to identify and assess the potency of alleged endocrine disruptors. In vitro assays could be used as an initial screen to identify endocrine-disrupting chemicals and complex mixtures. Results from these studies would prioritize chemicals that warrant further in vivo assessment and provide useful data for SARs that could also be developed to identify potential endocrine disruptors. The effect of alleged endocrine disruptors in vivo could then be investigated with attention directed to specific end points based on data obtained from in vitro assays. This strategy ensures that the most likely in vivo targets are assessed as endocrine disruption must be demonstrated in an in vivo model.
Future Prospects
Despite the rapid progress in cell and tissue culture techniques described in this paper, new methods provide only a limited amount of the information that is essential for the safety assessment of chemicals and that can sufficiently be obtained from testing in animals. Although significant progress has been made, in the near future in vitro tests will not allow evaluation of systemic and long-term effects of exposure to drugs and hazardous chemicals.
In contrast, in vitro methods are routinely used in mechanistic studies on the effects of toxic chemicals at the cellular and molecular level. Thus 
